EVENTS|NEWS|CONTACT|DONATE

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Read Our Newsletter

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Day

November 24, 2025

Research Scholar Investigates Novel Immune Target in Gastric Cancer

Over the past three years, Martina Molgora, PhD, has made the most of the opportunities that have come her way since she...

Social Media

Newsroom

For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org

Categories

Foundation News
Press Releases
Research News
Your New Normal

Tags

adenocarcenoma advanced stage alcohol antibody biomarker blood chemoradiotherapy chemotherapy clinical trial clinical trials detection drugs endoscopy Epstein-Barr esophagogastric FDA gastrectomy gastric cancer registry gastroesophageal genes heartburn helicobacter pylori HER2 immunotherapy keytruda lonsurf metastatic nutrition peritoneal postoperative prevention proton pump inhibitor recovery recurrence research risk screening side-effects studies surgery survival treatment tumor virus women

Gastric Cancer Foundation

Tax ID 27-2978173

info@gastriccancer.org

PO Box 6279
Albany, CA 94706

Site Map

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Social Feed

Gastric Cancer Foundation

4 days ago

A recently launched clinical trial will test whether a combination treatment including Daiichi Sankyo US’s HER2-targeted drug Enhertu (trastuzumab deruxtecan) might be effective in patients with HER2-low gastric cancer. Patients will receive a combination of Enhertu, chemotherapy and a novel antibody treatment, volrustomig, being developed by AstraZeneca US. The trial plan was presented at the recent American Society of Clinical Oncology GI Cancers Symposium. #ASCO2026 #GI26 ... See MoreSee Less

First-line (1L) trastuzumab deruxtecan (T-DXd) with volrustomig and fluoropyrimidine in patients with HER2-low gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): DESTINY-Gastric03 (DG-03) part...

www.asco.org

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

6 days ago

Efficacy data from a meta-analysis of clinical trials and real-world evidence presented at the American Society of Clinical Oncology GI Cancers Symposium supports the early-line use of Daiichi Sankyo US's Enhertu (trastuzumab deruxtecan) in patients with HER2-positive gastric cancer, the authors concluded. In the study, the pooled objective response rate was 47.7%. ... See MoreSee Less

Efficacy and safety of trastuzumab deruxtecan in HER2-positive advanced gastric and gastroesophageal junction cancers: A meta-analysis of real-world studies and clinical trials. - ASCO

www.asco.org

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

1 week ago

“Progress happens most often in partnership with others. When we come together as a community to share perspectives and ideas, to collaborate and to build on new scientific advances, it helps catalyze new areas of progress.” - Harriet Patterson, MPH, Executive Director, Gastric Cancer FoundationICYMI: Catch up on exciting updates following the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in our January newsletter - and subscribe for the latest foundation and research news! ... See MoreSee Less

New Connections and Exciting Research in Gastric Cancer

conta.cc

Email from Gastric Cancer Foundation There's still time to make an impact and commit to a cure DONATE Thank You for Powering Progress! Your generosity during our successful Commit to a Cure campai...

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

2 weeks ago

In a poster presentation at the American Society of Clinical Oncology GI Cancers Symposium, combining Taiho Oncology’s Lonsurf (trifluridine/tipiracil) with the VEGFR2 inhibitor Cyramza (ramucirumab) showed promising efficacy as a third-line or later treatment in advanced gastric cancer. ... See MoreSee Less

Efficacy and safety of trifluridine/tipiracil plus ramucirumab in advanced gastric cancer as third-line or later treatment: A multicenter phase II study. - ASCO

www.asco.org

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

2 weeks ago

Cancer is more than just a medical diagnosis. Behind every diagnosis lies a unique human story – stories of grief, pain, healing, resilience, love and more. Today, on World Cancer Day, Gastric Cancer Foundation recognizes that stomach cancer impacts so many aspects of a person's life and that each cancer journey is unique. That’s why a people-centered approach to cancer care that fully integrates each individual’s unique needs, with compassion and empathy, leads to the best health outcomes. Share your story with us here. #WorldCancerDay #UnitedByUnique World Cancer Day ... See MoreSee Less

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Subscribe to Our Newsletter

We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.

© 2024 Gastric Cancer Foundation. All Rights Reserved.

EVENTS | NEWS | CONTACT | DONATE

X